Fortis extends deadline of binding bids to 3 July

Published On 2018-06-29 08:14 GMT   |   Update On 2018-06-29 08:14 GMT

New Delhi: Cash-strapped Fortis Healthcare Ltd, which is currently in the process of finding a new investor, today extended the date for submission of binding bids yet again to 3 July.


Earlier on 12 June, the company had extended the deadline for submission of binding bids to 28 June after shortlisting four entities—the Munjal-Burman combine, Manipal-TPG consortium, Malaysia’s IHH Healthcare Berhad and Radiant Life Care—as possible suitors for the sale of its business.


The rest of the details with respect to the timings and submission remain the same, the company said in a BSE filing.


In May, Fortis Healthcare had initiated a fresh time- bound bidding process for its sale after terminating the offer made by the Munjal-Burman combine. It had set 14 June as the deadline for submitting fresh binding bids.


As per the criteria set by the company, the buyer have to make a minimum investment of Rs1,500 crore into Fortis Healthcare by way of preferential allotment apart from having a plan for funding the acquisition of RHT Health Trust (RHT) and a plan for providing exit to private equity investors of diagnostic arm SRL.


Among others, the bids should be unconditional as well as mention the source of funds for the transaction and elaborate on the plans for retention of current management and employees.


The latest development comes two days after the company announced that it has initiated legal action to recover about Rs500 crore of funds allegedly taken out of the company by its founders Malvinder and Shivinder Singh after an external investigation found “systemic lapses and override of controls” in the loan given.


At 1.08pm, Fortis shares were down 0.71% to Rs133.80 on BSE.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News